Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析

◆英語タイトル:Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81983FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Green Cross Cell Corp (031390) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Green Cross Cell Corp (GC Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of cord blood that contains stem cells, which can be used to treat various diseases such as pediatric cancer, leukemia, stroke, diabetes, and liver diseases, among others. GC Cell offers contract services ranging from manufacturing of the biopharmaceuticals, processing, cell storage, and consulting, to the product delivery. The company also carries out research programs targeted at the treatment of leukemia, pancreatic cancer, ovarian cancer, acquired immunodeficiency syndrome (AIDS) and glioblastoma. GC Cell is headquartered in Seoul, South Korea.

Green Cross Cell Corp Key Recent Developments

Dec 02,2020: GC Green Cross recruits executive director Jo Jung-rae as new head of business management
Nov 12,2020: GC Green Cross launches’Bmax Ever’, a high-content active vitamin for the elderly
Nov 02,2020: GC Green Cross, 3rd quarter sales of 420 billion won, the highest ever
Oct 28,2020: GC Green Cross Lab Cell, 3Q sales and operating profit record
Oct 20,2020: GC Green Cross Medical Foundation appoints Chairman Eunhee Lee

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Green Cross Cell Corp – Key Facts
Green Cross Cell Corp – Key Employees
Green Cross Cell Corp – Major Products and Services
Green Cross Cell Corp – History
Green Cross Cell Corp – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Green Cross Cell Corp – Business Description
R&D Overview
Green Cross Cell Corp – Corporate Strategy
Green Cross Cell Corp – SWOT Analysis
SWOT Analysis – Overview
Green Cross Cell Corp – Strengths
Green Cross Cell Corp – Weaknesses
Green Cross Cell Corp – Opportunities
Green Cross Cell Corp – Threats
Green Cross Cell Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 02, 2020: GC Green Cross recruits executive director Jo Jung-rae as new head of business management
Nov 12, 2020: GC Green Cross launches’Bmax Ever’, a high-content active vitamin for the elderly
Nov 02, 2020: GC Green Cross, 3rd quarter sales of 420 billion won, the highest ever
Oct 28, 2020: GC Green Cross Lab Cell, 3Q sales and operating profit record
Oct 20, 2020: GC Green Cross Medical Foundation appoints Chairman Eunhee Lee
Sep 08, 2020: GC Green Cross launches Korea’s only translucent acyclovir cream
Sep 04, 2020: Ubicare acquires a domestic patent for monitoring technology for suspected infectious diseases
Jul 30, 2020: GC Green Cross recorded 360 billion won in sales and 15.6 billion won in operating profit in the second quarter
Jul 30, 2020: UBI Care recorded 26.1 billion won in sales in the second quarter
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Green Cross Cell Corp, Key Facts
Green Cross Cell Corp, Key Employees
Green Cross Cell Corp, Major Products and Services
Green Cross Cell Corp, History
Green Cross Cell Corp, Key Competitors
Green Cross Cell Corp, Ratios based on current share price
Green Cross Cell Corp, Annual Ratios
Green Cross Cell Corp, Annual Ratios (Cont...1)
Green Cross Cell Corp, Annual Ratios (Cont...2)
Green Cross Cell Corp, Interim Ratios
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Siemens Gamesa Renewable Energy SA (SGRE):電力:M&Aディール及び事業提携情報
    Summary Siemens Gamesa Renewable Energy SA (SGRE), formerly Gamesa Corporacion Tecnologica, S.A., is a supplier of wind power solutions. The company designs, manufactures and sells wind turbines. The product portfolio of the company includes offshore and onshore products. It also provides industry-l …
  • Enea AB (ENEA):企業の財務・戦略的SWOT分析
    Summary Enea AB (Enea) is a technology company that provides software solutions. The company offers embedded technologies, testing and validation, certifications, software outsourcing, research and development centers, professional staffing and packaged services. It offers realtime operating system …
  • Hasbro Inc (HAS):企業の財務・戦略的SWOT分析
    Hasbro Inc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Vestas Wind Systems AS (VWS):電力:M&Aディール及び事業提携情報
    Summary Vestas Wind Systems A/S (Vestas) is a renewable energy company that designs, manufactures, constructs, installs, and services wind turbines. The company partners with customers to monitor wind energy production and performance of the wind power plant throughout its lifetime. It offers soluti …
  • N.V. Nationale Borg-Maatschappij:企業の戦略・SWOT・財務情報
    N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report Summary N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Carborundum Universal Ltd:企業の戦略・SWOT・財務情報
    Carborundum Universal Ltd - Strategy, SWOT and Corporate Finance Report Summary Carborundum Universal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Eris Lifesciences Ltd (Eris Lifesciences) is a pharmaceutical company that manufactures and commercializes generics products. The company through its divisions provides wide range of products including Maxum, Decal, Eritel H, Eritel CH 80 LS, Glimisave Max Forte 1, Mac Rabonik Plus, Vomisave …
  • Insys Therapeutics Inc (INSY):製薬・医療:M&Aディール及び事業提携情報
    Summary Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship prod …
  • SynDevRx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SynDevRx Inc (SDX) is a drug development company that develops treatments for cancer and metabolic dysfunction. The company offers lead compound SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active novel small molecule fumagillol derivative in vivo. Its servic …
  • OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Acorn Energy, Inc. (ACFN)-エネルギー分野:企業M&A・提携分析
    Summary Acorn Energy, Inc. (Acorn) is an energy technology holding company which operates electricity delivery, emergency back-up power generation, and remote monitoring and control systems through its subsidiaries. The company develops and produces sonar systems for the defense, HLS, energy and com …
  • Iron Mountain Incorporated:企業のM&A・事業提携・投資動向
    Iron Mountain Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iron Mountain Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Sino Land Co Ltd:企業の戦略・SWOT・財務情報
    Sino Land Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sino Land Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Acadia Pharmaceuticals Inc (ACAD):企業の財務・戦略的SWOT分析
    Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Eurofins MWG Operon LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofins MWG Operon LLC (Eurofins) is a DNA sequencing service provider. The company offers DNA sequencing services, DNA synthesis products, and bioinformatic services. Its product categories comprise DNA and RNA synthesis, DNA sequencing, GENE synthesis and next gen seq. Eurofins provides n …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Co) operates as a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments . The company’s products include powertrain testing systems, digital analog converter, DSP platform, mod …
  • TravelCenters of America LLC:企業の戦略・SWOT・財務情報
    TravelCenters of America LLC - Strategy, SWOT and Corporate Finance Report Summary TravelCenters of America LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Innovative Solutions and Support, Inc.:企業の戦略・SWOT・財務情報
    Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report Summary Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Huawei Technologies Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Huawei Technologies Co., Ltd. (Huawei), a subsidiary of Huawei Investment & Holding Co., Ltd, is an information and communication technology company. The company’s product portfolio includes mobile, broadband, core network, transmission network, and data communication products, besides value …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆